AstraZeneca braces for coronavirus hit, but no impact so far
Share:
(Reuters) - AstraZeneca forecast a likely slowdown in revenue growth this year, assuming a hit from China's coronavirus epidemic lasting up to a few months, although it added there had been limited disruption to its operations so far. Shares in the company, one of the world's major drugmakers, tumbled as much as 6% in early Friday trade after fourth-quarter results also missed analysts' expectations. However, they recovered after CEO Pascal Soriot played down the impact of the coronavirus..